Tempus AI TEM recently started working with leading academic medical centers to broaden access to advanced genomic testing and data-driven cancer care. In line with this, Tempus and NYU Langone Health have formed a multi-year partnership to improve cancer care using advanced genetic testing and data analysis. The collaboration is aimed at improving genetic diagnostics, helping doctors make better treatment decisions and accelerating the development of new tests and data-driven tools.
Beyond its role in next-generation sequencing (NGS) testing, the partnership expands Tempus’ involvement to test validation, biomarker discovery, disease modeling, real-world data analysis, and AI-driven prediction tools. This will support the routine use of ongoing molecular profiling at the Perlmutter Cancer Center, allowing doctors to better understand each patient’s cancer, tailor targeted treatments and track how tumors respond to therapy or develop resistance.
In addition, Northwestern Medicine and Tempus are also collaborating to make genomic testing available to more cancer patients at Northwestern Medicine. The collaboration is aimed at providing nearly all cancer patients, including those diagnosed at an early stage, access to genetic testing.
This testing will help doctors better understand each patient’s cancer and choose more personalized and effective treatments. Tempus will support Northwestern Medicine by providing a wide range of genomic tests, including tissue testing, DNA and RNA profiling, liquid biopsy and minimal residual disease (MRD) testing.
Peer Update
An expanding NGS oncology portfolio is helping Illumina ILMN drive the revolution in cancer genomics. In 2025, Illumina introduced TSO 500 v2, the next-generation version that offers built-in HRD biomarker detection and lower tissue sample input. In addition, Illumina is partnering with several global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TSO Comprehensive genomic profiling test, focusing on KRAS alterations, which are known to cause uncontrolled cell growth, leading to cancer.
Myriad Genetics MYGN has identified several opportunities to grow its Oncology business, including expanding the diagnostic offerings, adding indications and genes to existing oncology tests, reducing friction for providers with automated ordering and reporting and investing in clinical evidence generation. This year, MYGN plans to introduce Precise Liquid, a liquid biopsy therapy selection test that can serve as a first-line offering or as a reflex test if the solid tumor is insufficient. Myriad Genetics is also developing Precise MRD, a monitoring test based on whole-genome sequencing, to deeply interrogate tumors, detect cancer recurrence earlier and help guide treatment decisions.
TEM’s Stock Price Performance
Over the past year, Tempus’ shares have rallied 114.3% compared with the industry’s 4.3% growth. The S&P 500 composite has improved 22% in the same time frame.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 7.84X compared with the industry average of 5.77X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's loss per share estimate for 2025 has narrowed 1 cent to 64 cents.
Image Source: Zacks Investment Research
TEM currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpIllumina, Inc. (ILMN) : Free Stock Analysis Report
Myriad Genetics, Inc. (MYGN) : Free Stock Analysis Report
Tempus AI, Inc. (TEM) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
